CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO


20-October-2011
Certified Spiking Solutions® of the antipsychotic metabolite Norquetiapine HCl and anticonvulsant Rufinamide are now available.

Norquetiapine HCl, 1.0 mg/mL N-070
1.0 mg/mL (as free base) in Methanol

Norquetiapine is a primary active metabolite of quetiapine, marketed as the atypical antipsychotic Seroquel for the treatment of depression, bipolar disorder, and schizophrenia. It maintains most of the pharmacological effects of quetiapine with potencies similar to the parent drug.

Refer to R-023 R-015
500 ug/mL in Methanol

Rufinamide, marketed as Banzel® in the US and Inovelon® in the European Union, is a newer anticonvulsant and antiepileptic drug. The drug was approved by the US Food and Drug Administration (FDA) on November 14, 2008, for the treatment of partial seizures associated with Lennox-Gastaut syndrome in adults and children 4 years and older.

Cerilliant provides a wide selection of second-generation anticonvulsants and atypical antipsychotics including zonisamide, lamotrigine, levetiracetam, aripiprazole, 9-hydroxyrispierdone, quetiapine, and olanzapine.


Cerilliant Certified Solution Standards and Certified Spiking Solutions are manufactured to the highest industry standards. We are accredited to ISO Guide 34 and ISO/IEC 17025 & certified to ISO 13485 and ISO 9001. Our quality system also incorporates cGMP and GLP requirements


All New Product Announcements


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn